StockNews.com started coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research report report published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
22nd Century Group stock opened at $0.12 on Friday. The firm has a market cap of $1.01 million, a price-to-earnings ratio of 0.00 and a beta of 1.39. 22nd Century Group has a 1 year low of $0.09 and a 1 year high of $8.63. The firm’s 50 day moving average price is $0.28 and its two-hundred day moving average price is $0.80.
22nd Century Group (NASDAQ:XXII – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%. The company had revenue of $7.95 million for the quarter.
Institutional Inflows and Outflows
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
See Also
- Five stocks we like better than 22nd Century Group
- EV Stocks and How to Profit from Them
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Manufacturing Stocks Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Breakout Stocks: What They Are and How to Identify Them
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.